Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 298

1.

Dysglycemia and the Density of the Coronary Vasa Vasorum.

Gerstein HC, Nair V, Chaube R, Stoute H, Werstuck G.

Diabetes Care. 2019 Mar 12. pii: dc182483. doi: 10.2337/dc18-2483. [Epub ahead of print]

PMID:
30862652
2.

Effects of basal insulin glargine and omega-3 on lower limb arterial disease outcome in patients with dysglycaemia: An analysis of the Outcome Reduction with an Initial Glargine INtervention (ORIGIN) trial.

Dagenais GR, Jung H, Bogaty P, Bosch J, Yusuf S, Gerstein HC.

Diabetes Obes Metab. 2019 Feb 20. doi: 10.1111/dom.13674. [Epub ahead of print]

PMID:
30785660
3.

Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States.

Boye KS, Riddle MC, Gerstein HC, Mody R, Garcia-Perez LE, Karanikas CA, Lage MJ, Riesmeyer JS, Lakshmanan MC.

Diabetes Obes Metab. 2019 Feb 3. doi: 10.1111/dom.13649. [Epub ahead of print]

PMID:
30714309
4.

Real-world studies no substitute for RCTs in establishing efficacy.

Gerstein HC, McMurray J, Holman RR.

Lancet. 2019 Jan 19;393(10168):210-211. doi: 10.1016/S0140-6736(18)32840-X. No abstract available.

PMID:
30663582
5.

Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration.

Seferovic JP, Bentley-Lewis R, Claggett B, Diaz R, Gerstein HC, Køber LV, Lawson FC, Lewis EF, Maggioni AP, McMurray JJV, Probstfield JL, Riddle MC, Solomon SD, Tardif JC, Pfeffer MA.

J Diabetes Res. 2018 Dec 16;2018:1631263. doi: 10.1155/2018/1631263. eCollection 2018.

6.

The Diabetes Health Coaching Randomized Controlled Trial: Rationale, Design and Baseline Characteristics of Adults Living With Type 2 Diabetes.

Sherifali D, Brozic A, Agema P, Gerstein HC, Punthakee Z, McInnes N, O'Reilly D, Ibrahim S, Usman Ali RM.

Can J Diabetes. 2018 Oct 17. pii: S1499-2671(18)30747-0. doi: 10.1016/j.jcjd.2018.10.004. [Epub ahead of print]

PMID:
30578164
7.

Testosterone, sex hormone-binding globulin and risk of cardiovascular events: A report from the Outcome Reduction with an Initial Glargine Intervention trial.

Wang A, Arver S, Boman K, Gerstein HC, Fu Lee S, Hess S, Rydén L, Mellbin LG.

Eur J Prev Cardiol. 2018 Dec 19:2047487318819142. doi: 10.1177/2047487318819142. [Epub ahead of print]

PMID:
30567457
8.

Cognitive function in adolescence and the risk for premature diabetes and cardiovascular mortality in adulthood.

Twig G, Tirosh A, Derazne E, Haklai Z, Goldberger N, Afek A, Gerstein HC, Kark JD, Cukierman-Yaffe T.

Cardiovasc Diabetol. 2018 Dec 5;17(1):154. doi: 10.1186/s12933-018-0798-5.

9.

Insulin use for type 2 diabetes: the challenges of predicting trends and modelling care.

Gerstein HC.

Lancet Diabetes Endocrinol. 2019 Jan;7(1):4-5. doi: 10.1016/S2213-8587(18)30312-7. Epub 2018 Nov 21. No abstract available.

PMID:
30470519
10.

Hypoglycemia and Incident Cognitive Dysfunction: A Post Hoc Analysis From the ORIGIN Trial.

Cukierman-Yaffe T, Bosch J, Jung H, Punthakee Z, Gerstein HC.

Diabetes Care. 2019 Jan;42(1):142-147. doi: 10.2337/dc18-0690. Epub 2018 Nov 13.

PMID:
30425095
11.

A Mendelian Randomization-Based Approach to Identify Early and Sensitive Diagnostic Biomarkers of Disease.

Mohammadi-Shemirani P, Sjaarda J, Gerstein HC, Treleaven DJ, Walsh M, Mann JF, McQueen MJ, Hess S, Paré G.

Clin Chem. 2019 Mar;65(3):427-436. doi: 10.1373/clinchem.2018.291104. Epub 2018 Oct 18.

PMID:
30337280
12.

Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial.

Morieri ML, Gao H, Pigeyre M, Shah HS, Sjaarda J, Mendonca C, Hastings T, Buranasupkajorn P, Motsinger-Reif AA, Rotroff DM, Sigal RJ, Marcovina SM, Kraft P, Buse JB, Wagner MJ, Gerstein HC, Mychaleckyj JC, Parè G, Doria A.

Diabetes Care. 2018 Nov;41(11):2404-2413. doi: 10.2337/dc18-0709. Epub 2018 Sep 27.

PMID:
30262460
13.

The association of basal insulin treatment versus standard care with outcomes in anti-GAD positive and negative subjects: A post-hoc analysis of the ORIGIN trial.

Birkeland KI, Grill V, Wium C, McQueen MJ, Lopez-Jaramillo P, Lee SF, Gerstein HC.

Diabetes Obes Metab. 2019 Feb;21(2):429-433. doi: 10.1111/dom.13528. Epub 2018 Oct 3.

PMID:
30203580
14.

Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study.

Chow CK, Ramasundarahettige C, Hu W, AlHabib KF, Avezum A Jr, Cheng X, Chifamba J, Dagenais G, Dans A, Egbujie BA, Gupta R, Iqbal R, Ismail N, Keskinler MV, Khatib R, Kruger L, Kumar R, Lanas F, Lear S, Lopez-Jaramillo P, McKee M, Mohammadifard N, Mohan V, Mony P, Orlandini A, Rosengren A, Vijayakumar K, Wei L, Yeates K, Yusoff K, Yusuf R, Yusufali A, Zatonska K, Zhou Y, Islam S, Corsi D, Rangarajan S, Teo K, Gerstein HC, Yusuf S; PURE investigators.

Lancet Diabetes Endocrinol. 2018 Oct;6(10):798-808. doi: 10.1016/S2213-8587(18)30233-X. Epub 2018 Aug 28.

PMID:
30170949
15.

Minimally important difference and predictors of change in quality of life in type 2 diabetes: A community-based survey in China.

Jin X, Liu GG, Gerstein HC, Levine MAH, Guan H, Li H, Xie F.

Diabetes Metab Res Rev. 2018 Nov;34(8):e3053. doi: 10.1002/dmrr.3053. Epub 2018 Aug 31.

PMID:
30064154
16.

Association of preoperative glucose concentration with myocardial injury and death after non-cardiac surgery (GlucoVISION): a prospective cohort study.

Punthakee Z, Iglesias PP, Alonso-Coello P, Gich I, India I, Malaga G, Jover RD, Gerstein HC, Devereaux PJ.

Lancet Diabetes Endocrinol. 2018 Oct;6(10):790-797. doi: 10.1016/S2213-8587(18)30205-5. Epub 2018 Jul 26.

PMID:
30057170
17.

A1C Targets Should Be Personalized to Maximize Benefits While Limiting Risks.

Riddle MC, Gerstein HC, Holman RR, Inzucchi SE, Zinman B, Zoungas S, Cefalu WT.

Diabetes Care. 2018 Jun;41(6):1121-1124. doi: 10.2337/dci18-0018. No abstract available.

PMID:
29784695
18.

Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants.

Theodorakis MJ, Coleman RL, Feng H, Chan J, Chiasson JL, Ge J, Gerstein HC, Huo Y, Lang Z, McMurray JJ, Rydén L, Schröder S, Tendera M, Tuomilehto J, Yang W, Hu D, Pan C, Holman RR; ACE Study Group.

Am Heart J. 2018 May;199:170-175. doi: 10.1016/j.ahj.2017.09.001. Epub 2017 Sep 8. No abstract available.

PMID:
29754657
19.

Item reduction and validation of the Chinese version of diabetes quality-of-life measure (DQOL).

Jin X, Liu GG, Gerstein HC, Levine MAH, Steeves K, Guan H, Li H, Xie F.

Health Qual Life Outcomes. 2018 Apr 27;16(1):78. doi: 10.1186/s12955-018-0905-z.

20.

Newly diagnosed type 2 diabetes may serve as a potential marker for pancreatic cancer.

Dankner R, Freedman LS, Gerstein HC, Roth J, Keinan-Boker L.

Diabetes Metab Res Rev. 2018 Sep;34(6):e3018. doi: 10.1002/dmrr.3018. Epub 2018 Jun 17.

PMID:
29673046
21.

Blood HER2 and Uromodulin as Causal Mediators of CKD.

Sjaarda J, Gerstein HC, Yusuf S, Treleaven D, Walsh M, Mann JFE, Hess S, Paré G.

J Am Soc Nephrol. 2018 Apr;29(4):1326-1335. doi: 10.1681/ASN.2017070812. Epub 2018 Mar 6.

PMID:
29511113
22.

Do sulphonylureas still have a place in clinical practice?

Khunti K, Chatterjee S, Gerstein HC, Zoungas S, Davies MJ.

Lancet Diabetes Endocrinol. 2018 Oct;6(10):821-832. doi: 10.1016/S2213-8587(18)30025-1. Epub 2018 Feb 28. Review.

PMID:
29501322
23.

Cardiovascular Outcomes Trials of Glucose-Lowering Drugs or Strategies in Type 2 Diabetes.

Gerstein HC, Shah R.

Endocrinol Metab Clin North Am. 2018 Mar;47(1):97-116. doi: 10.1016/j.ecl.2017.10.003. Epub 2017 Nov 20. Review.

PMID:
29407059
24.

Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals.

Aung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L, Geleijnse JM, Rauch B, Ness A, Galan P, Chew EY, Bosch J, Collins R, Lewington S, Armitage J, Clarke R; Omega-3 Treatment Trialists’ Collaboration.

JAMA Cardiol. 2018 Mar 1;3(3):225-234. doi: 10.1001/jamacardio.2017.5205.

25.

Determinants of cognitive function in individuals with type 2 diabetes mellitus: A meta-analysis.

Mansur RB, Lee Y, Zhou AJ, Carmona NE, Cha DS, Rosenblat JD, Bruins R, Kakar R, Rasgon NL, Lovshin JA, Wroolie TE, Sim K, Brietzke E, Gerstein HC, Rong C, McIntyre RS.

Ann Clin Psychiatry. 2018 Feb;30(1):38-50.

PMID:
29373617
26.

Effect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure Hospitalization: The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention).

Gerstein HC, Jung H, Rydén L, Diaz R, Gilbert RE, Yusuf S; ORIGIN Investigators.

Circulation. 2018 Jan 2;137(1):88-90. doi: 10.1161/CIRCULATIONAHA.117.030924. No abstract available.

PMID:
29279340
27.

Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum.

Cefalu WT, Kaul S, Gerstein HC, Holman RR, Zinman B, Skyler JS, Green JB, Buse JB, Inzucchi SE, Leiter LA, Raz I, Rosenstock J, Riddle MC.

Diabetes Care. 2018 Jan;41(1):14-31. doi: 10.2337/dci17-0057.

28.

Penetrance of Polygenic Obesity Susceptibility Loci across the Body Mass Index Distribution.

Abadi A, Alyass A, Robiou du Pont S, Bolker B, Singh P, Mohan V, Diaz R, Engert JC, Yusuf S, Gerstein HC, Anand SS, Meyre D.

Am J Hum Genet. 2017 Dec 7;101(6):925-938. doi: 10.1016/j.ajhg.2017.10.007.

29.

Modulation of GLP-1 Levels by a Genetic Variant That Regulates the Cardiovascular Effects of Intensive Glycemic Control in ACCORD.

Shah HS, Morieri ML, Marcovina SM, Sigal RJ, Gerstein HC, Wagner MJ, Motsinger-Reif AA, Buse JB, Kraft P, Mychaleckyj JC, Doria A.

Diabetes Care. 2018 Feb;41(2):348-355. doi: 10.2337/dc17-1638. Epub 2017 Nov 28.

30.

Maturation of CGM and Glycemic Measurements Beyond HbA1c-A Turning Point in Research and Clinical Decisions.

Riddle MC, Gerstein HC, Cefalu WT.

Diabetes Care. 2017 Dec;40(12):1611-1613. doi: 10.2337/dci17-0049. No abstract available.

PMID:
29162581
31.

Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus.

Wolsk E, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber L, Lawson FC, Lewis EF, Maggioni AP, McMurray JJV, Probstfield JL, Riddle MC, Solomon SD, Tardif JC, Pfeffer MA.

Circulation. 2017 Oct 17;136(16):1560-1562. doi: 10.1161/CIRCULATIONAHA.117.029503. No abstract available.

PMID:
29038210
32.

Optimizing the methodology for measuring supraclavicular skin temperature using infrared thermography; implications for measuring brown adipose tissue activity in humans.

Haq T, Crane JD, Kanji S, Gunn E, Tarnopolsky MA, Gerstein HC, Steinberg GR, Morrison KM.

Sci Rep. 2017 Sep 20;7(1):11934. doi: 10.1038/s41598-017-11537-x.

33.

Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.

Holman RR, Coleman RL, Chan JCN, Chiasson JL, Feng H, Ge J, Gerstein HC, Gray R, Huo Y, Lang Z, McMurray JJ, Rydén L, Schröder S, Sun Y, Theodorakis MJ, Tendera M, Tucker L, Tuomilehto J, Wei Y, Yang W, Wang D, Hu D, Pan C; ACE Study Group.

Lancet Diabetes Endocrinol. 2017 Nov;5(11):877-886. doi: 10.1016/S2213-8587(17)30309-1. Epub 2017 Sep 13. Erratum in: Lancet Diabetes Endocrinol. 2017 Nov;5(11):e7.

PMID:
28917545
34.

Insulin resistance and cardiovascular outcomes in the ORIGIN trial.

Gerstein HC, Ferrannini E, Riddle MC, Yusuf S; ORIGIN Trial Investigators.

Diabetes Obes Metab. 2018 Mar;20(3):564-570. doi: 10.1111/dom.13112. Epub 2017 Oct 8.

PMID:
28895655
35.

Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study.

Papademetriou V, Nylen ES, Doumas M, Probstfield J, Mann JFE, Gilbert RE, Gerstein HC.

Am J Med. 2017 Dec;130(12):1465.e27-1465.e39. doi: 10.1016/j.amjmed.2017.05.047. Epub 2017 Aug 31.

PMID:
28842165
36.

Effect of insulin glargine on recreational physical activity and TV viewing: Analysis of the randomised ORIGIN trial.

Yates T, Davies MJ, Jung H, Bosch J, Spinas GA, Sreenan S, Commerford P, Gerstein HC; ORGIN investigators.

Diabetes Res Clin Pract. 2017 Oct;132:137-143. doi: 10.1016/j.diabres.2017.07.035. Epub 2017 Jul 31.

PMID:
28837885
37.

Microvascular outcomes in type 2 diabetes - Authors' reply.

Zoungas S, Gerstein HC, Holman RR, Reaven P, Woodward M, Arima H, Coleman RL, Chalmers J; Collaborators on Trials of Lowering Glucose (CONTROL) writing group.

Lancet Diabetes Endocrinol. 2017 Aug;5(8):580. doi: 10.1016/S2213-8587(17)30185-7. No abstract available.

PMID:
28732664
38.

The Relationship Between the Score on a Simple Measure of Cognitive Function and Incident CVD in People With Diabetes: A Post Hoc Epidemiological Analysis From the ACCORD-MIND Study.

Cukierman-Yaffe T, Gerstein HC, Miller ME, Launer LJ, Williamson JD, Horowitz KR, Ismail-Beigi F, Lazar RM.

J Clin Endocrinol Metab. 2017 Sep 1;102(9):3218-3225. doi: 10.1210/jc.2016-3480.

39.

Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide.

Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riddle MC, Rydén L, Xavier D, Atisso CM, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona-Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw J, Sheu WH, Temelkova-Kurktschiev T; REWIND Trial Investigators.

Diabetes Obes Metab. 2018 Jan;20(1):42-49. doi: 10.1111/dom.13028. Epub 2017 Jul 14.

PMID:
28573765
40.

Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus.

Wolsk E, Claggett B, Pfeffer MA, Diaz R, Dickstein K, Gerstein HC, Lawson FC, Lewis EF, Maggioni AP, McMurray JJV, Probstfield JL, Riddle MC, Solomon SD, Tardif JC, Køber L.

J Am Heart Assoc. 2017 May 29;6(6). pii: e004743. doi: 10.1161/JAHA.116.004743.

41.

Influence of depression on genetic predisposition to type 2 diabetes in a multiethnic longitudinal study.

Garasia S, Samaan Z, Gerstein HC, Engert JC, Mohan V, Diaz R, Anand SS, Meyre D.

Sci Rep. 2017 May 9;7(1):1629. doi: 10.1038/s41598-017-01406-y.

42.

The effect of basal insulin glargine on the fibrinolytic system and von Willebrand factor in people with dysglycaemia and high risk for cardiovascular events: Swedish substudy of the Outcome Reduction with an Initial Glargine Intervention trial.

Rautio A, Boman K, Gerstein HC, Hernestål-Boman J, Lee SF, Olofsson M, Mellbin LG.

Diab Vasc Dis Res. 2017 Jul;14(4):345-352. doi: 10.1177/1479164117703034. Epub 2017 Apr 12.

PMID:
28403644
43.

Validation of the ORIGIN Cardiovascular Biomarker Panel and the Value of Adding Troponin I in Dysglycemic People.

Gerstein HC, Paré G, McQueen MJ, Lee SF, Hess S; ORIGIN Trial Investigators.

J Clin Endocrinol Metab. 2017 Jul 1;102(7):2251-2257. doi: 10.1210/jc.2017-00273.

PMID:
28368516
44.

Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials.

Zoungas S, Arima H, Gerstein HC, Holman RR, Woodward M, Reaven P, Hayward RA, Craven T, Coleman RL, Chalmers J; Collaborators on Trials of Lowering Glucose (CONTROL) group.

Lancet Diabetes Endocrinol. 2017 Jun;5(6):431-437. doi: 10.1016/S2213-8587(17)30104-3. Epub 2017 Mar 30.

PMID:
28365411
45.

Piloting a Remission Strategy in Type 2 Diabetes: Results of a Randomized Controlled Trial.

McInnes N, Smith A, Otto R, Vandermey J, Punthakee Z, Sherifali D, Balasubramanian K, Hall S, Gerstein HC.

J Clin Endocrinol Metab. 2017 May 1;102(5):1596-1605. doi: 10.1210/jc.2016-3373.

PMID:
28324049
46.

Response to Comment on Cefalu et al. Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum. Diabetes Care 2016;39:1186-1201.

Cefalu WT, Buse JB, Tuomilehto J, Fleming GA, Ferrannini E, Gerstein HC, Bennett PH, Ramachandran A, Raz I, Rosenstock J, Kahn SE.

Diabetes Care. 2017 Feb;40(2):e23-e24. doi: 10.2337/dci16-0036. No abstract available.

47.

Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.

Elam MB, Ginsberg HN, Lovato LC, Corson M, Largay J, Leiter LA, Lopez C, O'Connor PJ, Sweeney ME, Weiss D, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm R, Ismail-Beigi F, Goff DC Jr, Fleg JL, Rosenberg Y, Byington RP; ACCORDION Study Investigators.

JAMA Cardiol. 2017 Apr 1;2(4):370-380. doi: 10.1001/jamacardio.2016.4828.

48.

Growth Differentiation Factor 15 as a Novel Biomarker for Metformin.

Gerstein HC, Pare G, Hess S, Ford RJ, Sjaarda J, Raman K, McQueen M, Lee S, Haenel H, Steinberg GR; ORIGIN Investigators.

Diabetes Care. 2017 Feb;40(2):280-283. doi: 10.2337/dc16-1682. Epub 2016 Dec 14.

PMID:
27974345
49.

ACCORDION MIND: results of the observational extension of the ACCORD MIND randomised trial.

Murray AM, Hsu FC, Williamson JD, Bryan RN, Gerstein HC, Sullivan MD, Miller ME, Leng I, Lovato LL, Launer LJ; Action to Control Cardiovascular Risk in Diabetes Follow-On Memory in Diabetes (ACCORDION MIND) Investigators.

Diabetologia. 2017 Jan;60(1):69-80. Epub 2016 Oct 20.

50.

BMI at Age 17 Years and Diabetes Mortality in Midlife: A Nationwide Cohort of 2.3 Million Adolescents.

Twig G, Tirosh A, Leiba A, Levine H, Ben-Ami Shor D, Derazne E, Haklai Z, Goldberger N, Kasher-Meron M, Yifrach D, Gerstein HC, Kark JD.

Diabetes Care. 2016 Nov;39(11):1996-2003. Epub 2016 Oct 12.

PMID:
27733421

Supplemental Content

Loading ...
Support Center